COVID-19

This is how WHO is ensuring equal international access to a COVID-19 vaccine

A laboratory technician of biotechnology company mAbxience is seen working, amid the outbreak of the coronavirus disease (COVID-19), in Buenos Aires, Argentina August 13, 2020. REUTERS/Agustin Marcarian - RC29DI9XQTQP

COVAX aims to deliver 2 billion doses of effective, approved COVID-19 vaccines by the end of 2021. Image: REUTERS/Agustin Marcarian

Carl O'Donnell
Reporter , Reuters
Share:
Our Impact
What's the World Economic Forum doing to accelerate action on COVID-19?
The Big Picture
Explore and monitor how COVID-19 is affecting economies, industries and global issues
A hand holding a looking glass by a lake
Crowdsource Innovation
Get involved with our crowdsourced digital platform to deliver impact at scale
Stay up to date:

COVID-19

  • The Director-General of the WHO has warned against 'vaccine nationalism', where less economically developed countries might lose out.
  • The COVAX global vaccines facility is designed to pool funds to develop a COVID-19 vaccine and distribute it equitably around the world.
  • Its aim is to deliver 2 billion doses of effective, approved COVID-19 vaccines by the end of 2021.

The World Health Organization (WHO) on Tuesday urged countries to join a global pact aimed at ensuring less wealthy countries have access to COVID-19 vaccines, warning about the risks from so-called “vaccine nationalism.” Here is a look at the WHO’s plan and the approaches by wealthier nations.

A woman holds a small bottle labeled with a
COVAX is working to ensure fair access to COVID-19 vaccines. Image: Reuters/Dado Ruvic/Illustration
Have you read?

What is the WHOs vaccine program?

The COVAX global vaccines facility is a program designed to pool funds from wealthier countries and nonprofits to develop a COVID-19 vaccine and distribute it equitably around the world. Its aim is to deliver 2 billion doses of effective, approved COVID-19 vaccines by the end of 2021.

The details of the program are still being hashed out ahead of an Aug. 31 deadline for nations to join. It is led by the WHO, along with the Gavi vaccine alliance, and the Coalition for Epidemic Preparedness Innovations (CEPI).

COVAX is part of a broader program, called the Access to COVID-19 Tools (ACT) Accelerator, that works to ensure that vaccines, treatments, diagnostic tests and other healthcare resources are broadly available to combat the pandemic.

What are the wealthier nations doing?

They have focused on securing vaccines for their own citizens, striking deals for the first doses even as data has yet to prove the vaccines to be effective.

Governments including United States, the United Kingdom, Japan, and the European Union have spent tens of billions of dollars on deals with vaccine makers such as Pfizer Inc (PFE.N), Johnson & Johnson (JNJ.N), AstraZeneca Plc (AZN.L) and others. The United States alone has committed nearly $11 billion for development, testing, manufacture and stockpiling of hundreds of millions of doses.

Russia and China are also working on vaccines and have already begun vaccinating some of their citizens.

What kind of resources are being brought to bear?

The ACT Accelerator is financed by a variety of nonprofits and governments. It is aiming to raise about $31 billion.

So far, the COVAX facility has attracted interest from 92 poorer countries hoping for voluntary donations and 80 wealthier countries, a number little changed from a month ago, that would finance the scheme, according to the WHO.

What is the WHO's concern?

The WHO has expressed concern that wealthier countries hoarding vaccines for their own citizens could impede efforts to end the pandemic.

“We need to prevent vaccine nationalism,” WHO chief Tedros Adhanom Ghebreyesus said during a Tuesday virtual briefing. “Sharing finite supplies strategically and globally is actually in each country’s national interest.”

WHO leaders have said that developing a coordinated global distribution system for COVID-19 vaccines that prioritize those at greatest risk of getting sick, such as healthcare workers, would help curb the spread of coronavirus worldwide.

Loading...
Loading...
Don't miss any update on this topic

Create a free account and access your personalized content collection with our latest publications and analyses.

Sign up for free

License and Republishing

World Economic Forum articles may be republished in accordance with the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International Public License, and in accordance with our Terms of Use.

The views expressed in this article are those of the author alone and not the World Economic Forum.

Related topics:
COVID-19Global HealthGlobal Governance
Share:
World Economic Forum logo
Global Agenda

The Agenda Weekly

A weekly update of the most important issues driving the global agenda

Subscribe today

You can unsubscribe at any time using the link in our emails. For more details, review our privacy policy.

Winding down COVAX – lessons learnt from delivering 2 billion COVID-19 vaccinations to lower-income countries

Charlotte Edmond

January 8, 2024

About Us

Events

Media

Partners & Members

  • Join Us

Language Editions

Privacy Policy & Terms of Service

© 2024 World Economic Forum